1. Home
  2. TVRD vs EVC Comparison

TVRD vs EVC Comparison

Compare TVRD & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • EVC
  • Stock Information
  • Founded
  • TVRD 2017
  • EVC 1996
  • Country
  • TVRD United States
  • EVC United States
  • Employees
  • TVRD N/A
  • EVC N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • EVC Broadcasting
  • Sector
  • TVRD Health Care
  • EVC Industrials
  • Exchange
  • TVRD Nasdaq
  • EVC Nasdaq
  • Market Cap
  • TVRD 246.5M
  • EVC 233.8M
  • IPO Year
  • TVRD N/A
  • EVC 2000
  • Fundamental
  • Price
  • TVRD $3.91
  • EVC $2.71
  • Analyst Decision
  • TVRD Buy
  • EVC
  • Analyst Count
  • TVRD 7
  • EVC 0
  • Target Price
  • TVRD $51.67
  • EVC N/A
  • AVG Volume (30 Days)
  • TVRD 160.8K
  • EVC 989.3K
  • Earning Date
  • TVRD 11-13-2025
  • EVC 11-04-2025
  • Dividend Yield
  • TVRD N/A
  • EVC 7.43%
  • EPS Growth
  • TVRD N/A
  • EVC N/A
  • EPS
  • TVRD N/A
  • EVC N/A
  • Revenue
  • TVRD N/A
  • EVC $420,178,000.00
  • Revenue This Year
  • TVRD N/A
  • EVC $64.06
  • Revenue Next Year
  • TVRD N/A
  • EVC N/A
  • P/E Ratio
  • TVRD N/A
  • EVC N/A
  • Revenue Growth
  • TVRD N/A
  • EVC 24.96
  • 52 Week Low
  • TVRD $3.78
  • EVC $1.58
  • 52 Week High
  • TVRD $43.65
  • EVC $3.15
  • Technical
  • Relative Strength Index (RSI)
  • TVRD 21.48
  • EVC 58.27
  • Support Level
  • TVRD $3.78
  • EVC $2.68
  • Resistance Level
  • TVRD $4.15
  • EVC $2.77
  • Average True Range (ATR)
  • TVRD 0.31
  • EVC 0.16
  • MACD
  • TVRD 0.90
  • EVC -0.02
  • Stochastic Oscillator
  • TVRD 19.40
  • EVC 29.59

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: